Ioflupane (123I)

4 trials 1 recruiting VVarious

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

2 Completed trials

4 Sponsors

10 Countries

Phase II/III

Phase II

Phase II/III: 1 Phase II: 3

Oversight events:

1 temporary halt 1 unexpected event across 2 trials

View oversight register →

Indications tested

Parkinson's disease 2

Sponsors using this IMP

AC Immune S.A. 1 Biohaven Therapeutics Ltd. 1 Eip Pharma Inc. 1 UCB Biopharma 1

All trials

4 total

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Phase II/III 10 countries Biohaven Therapeutics Ltd.
An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, … Recruiting

2022-500292-31-00 Phase II 2 countries AC Immune S.A.
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB) Ended

2023-504373-20-00 Phase II 1 country Eip Pharma Inc.
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Phase II 6 countries UCB Biopharma

Showing 1–4 of 4 trials

← All drugs A–Z